See the DrugPatentWatch profile for Kovaltry
What Kovaltry patents cover (and who owns them)?
Kovaltry (antihemophilic factor [recombinant] for hemophilia A) is protected by a mix of patent types that typically include composition-of-matter claims (covering the recombinant factor itself), formulation/drug-product claims (how it’s made and packaged), and method-of-use claims (such as dosing or treating hemophilia A). The specific patent numbers, assignees, and claim scope depend on the country/region you’re looking at (for example, the US vs. EU vs. UK), since filings and grants vary by jurisdiction.
When do Kovaltry patents expire?
Patent expiration for Kovaltry is not a single date because:
- Different patents expire at different times (composition vs. formulation vs. method-of-use).
- Some patents may expire earlier and others later.
- Regulatory exclusivities (which are not the same as patents) can extend market protection even after certain patents lapse.
Exact expiration timelines require checking the patent register for the target country (and, in the US, often pairing Orange Book listings with individual patent expiration dates).
Can biosimilars enter before Kovaltry’s patents expire?
In many markets, biosimilar makers can seek approval based on biosimilar pathways while patents are still active, but they usually cannot be marketed until relevant patent barriers are cleared (through expiry, a settlement, or a court ruling). The timing depends on which Kovaltry patents are asserted and what they cover (product vs. method claims), as well as local rules for patent “linkage” between approval and exclusivity.
Where to look up Kovaltry patent listings (practical search locations)?
To find Kovaltry patent details accurately, use the primary public registers for your jurisdiction:
- US: FDA’s reference product listings (commonly via the Orange Book) and associated patent expiration dates, plus FDA labeling.
- EU/UK: national and EPO patent databases, plus national enforcement records where available.
- Other regions: local patent-office databases and government gazettes.
Are there patent disputes or challenged patents for Kovaltry?
Patent disputes around biologics typically involve questions like whether a biosimilar infringes specific claims, or whether certain claims are invalid. Whether Kovaltry has active or past disputes depends on the country and on which biosimilar applicants were involved. Those details are best confirmed in court records and regulator-linked patent listings for the jurisdiction you care about.
If you tell me the country, I can narrow to exact patent numbers and dates
“Kovaltry patents” changes materially by country. If you share the jurisdiction (for example, US, UK, Germany, France, Canada, Australia), I can help identify the relevant patent listings to check and what those patents generally cover (and how they map to biosimilar entry timing).
Sources
I don’t have any Kovaltry-specific patent register entries or named patent numbers provided in your prompt, so I can’t cite exact patent numbers or expiration dates yet. If you want, paste a link or the patent list you found (or tell me the country), and I’ll extract the key expiration dates and what each patent covers.